<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We write with respect to the recent publication by Nandakoban et al </plain></SENT>
<SENT sid="1" pm="."><plain>[1] describing a case of <z:hpo ids='HP_0004729'>acute tubulointerstitial nephritis</z:hpo> in a patient treated with exenatide </plain></SENT>
<SENT sid="2" pm="."><plain>Of interest, a recent manuscript by Pendergrass et al </plain></SENT>
<SENT sid="3" pm="."><plain>[2] described no association between exenatide and <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> in patients with Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Exenatide has been widely used in the UK over the past 4 years to treat Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in combination with <z:chebi fb="0" ids="6801">metformin</z:chebi> and/or sulphonylurea in patients with inadequate glycaemic control. © 2012 The Authors </plain></SENT>
<SENT sid="5" pm="."><plain>Diabetic Medicine © 2012 <z:mp ids='MP_0002055'>Diabetes</z:mp> UK </plain></SENT>
</text></document>